Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Shifting CAR-Ts Into a Higher Gear

EP Vantage Pharma & Biotech 2016 in Review EP Vantage Pharma & Biotech 2016 in Review EP Vantage Pharma & Biotech 2016 in Review

Download Report

EP Vantage Shifting CAR-Ts Into a Higher Gear

Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at.

This comprehensive report analyses:

  • The complexity and expense of manufacturing
  • The poor durability of many current CAR constructs
  • The growing ways by which tumour cells can become resistant to CAR-T therapy
  • The fear of severe toxicities
  • The cost and reimbursement questions surrounding CAR-T treatments

Press Release

Confirm your details on form below to download this report